The 4th International Lafora Epilepsy Workshop: Shifting paradigms, paths to treatment, and hope for patients

M. Kathryn Brewer, Tamar R. Grossman, Tracy R. McKnight, Y. Paul Goldberg, Hal Landy, Matthew S. Gentry

Research output: Contribution to journalArticlepeer-review

8 Scopus citations
Original languageEnglish
Pages (from-to)284-286
Number of pages3
JournalEpilepsy and Behavior
Volume90
DOIs
StatePublished - Jan 2019

Bibliographical note

Funding Information:
Drs. Grossman and Goldberg are employees of Ionis Pharmaceuticals. Drs. Landy and McKnight are employed by Valerion Therapeutics. Dr. Gentry has a sponsored project funded by Valerion Therapeutics.

Funding Information:
Research reported in this publication is supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Numbers R01NS070899 and P01NS097197. We thank Ms. Cheylene Plummer at the University of Kentucky College of Medicine for logistical support and planning the event.

Funding Information:
Research reported in this publication is supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Numbers R01NS070899 and P01NS097197 . We thank Ms. Cheylene Plummer at the University of Kentucky College of Medicine for logistical support and planning the event.

Funding Information:
The 4th International Lafora Disease Workshop was held in La Jolla, California, USA at the Sanford Consortium for Regenerative Medicine on September 6–8, 2018. The meeting was organized and hosted by Dr. Matthew Gentry, Director of the Lafora Epilepsy Cure Initiative (LECI) and Professor at the University of Kentucky College of Medicine, Drs. Kim and Jim Rice of Chelsea's Hope Lafora Children's Research Fund, and Drs. Jack Dixon and Carolyn Worby of University of California, San Diego (UC-San Diego). The workshop was sponsored by Chelsea's Hope, the National Institute of Neurological Disease and Stroke (NIH NINDS P01 NS097197), Valerion Therapeutics, Ionis Pharmaceuticals, Third Rock Ventures, and the Dixon Laboratory. The workshop was attended by nearly 100 students, postdoctoral scholars, clinicians, academic and company scientists, and the National Institutes of Health (NIH) representation from the United States, Spain, Canada, Turkey, India, Italy, France, and Australia as well as approximately 25 friends and family members of patients with Lafora disease (LD) from the US, the Netherlands, United Kingdom, and the Bahamas ( Fig. 1 ).

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Fingerprint

Dive into the research topics of 'The 4th International Lafora Epilepsy Workshop: Shifting paradigms, paths to treatment, and hope for patients'. Together they form a unique fingerprint.

Cite this